Posted
Nov 1 - Pharma giant Amgen is buying a fifth of China biotech star BeiGene for $2.7 bln. A 36% premium seems steep when the target has just shaken off a short-seller attack. But it’s a chance to crack a growing market for cancer drugs, Katrina Hamlin tells Pete Sweeney.
01:42
01:19
01:57
02:11
01:13
03:02
01:29
02:29
02:41
01:53
01:05
02:20
01:14
01:35
01:49
02:43
01:33
01:21
01:09
00:26
01:54
01:43
01:30
02:44
00:45
01:56
00:59
00:52
00:45
01:50
01:21
02:19
02:22
00:36
00:58
01:54
01:19
01:58
01:12
00:35
01:48
02:57
01:36
02:00
02:44
01:25
00:48
01:18
00:45
02:49
02:16
01:16
02:26
00:38
01:18
01:37